AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22442346 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular complete response (CR) after consolidation chemotherapy
Number of subjects: 580
Study 22442346 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular failure without stem cell transplantation (SCT) in first CR
Number of subjects: 580
Study 22442346 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative MRD assessment
Number of subjects: 580
Study 22443231 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL ropivacaine 0.75%
Number of subjects: 36
Study 22443231 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL ropivacaine 0.75%
Number of subjects: 36
Study 22443231 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL ropivacaine 0.75%
Number of subjects: 36
Study 22443231 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 22443293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (50-250 mg bid) during a 5-week titration and 7-week maintenance period.
Number of subjects: 175
Study 22443293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release treatment for patients with neuropathic pain component.
Number of subjects: 175
Study 22443293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release overall.
Number of subjects: 175
Study 22443344 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria Rapid Diagnostic Tests (RDTs)
Number of subjects: 190
Study 22443344 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 190
Study 22443344 — intervention group
Group type: COMPARATOR
Intervention: Polymerase Chain Reaction (PCR)
Number of subjects: 190
Study 22443802 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant short course intensity-modulated radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy)
Number of subjects: 46
Study 22445005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife stereotactic radiosurgery (SRS) boost to areas of high risk determined by magnetic resonance spectroscopy (MRS) functional imaging in addition to standard radiotherapy.
Number of subjects: 35
Study 22445005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife stereotactic radiosurgery (SRS) boost with standard radiotherapy.
Number of subjects: 35
Study 22445005 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent temozolomide with protocol radiotherapeutic treatment.
Number of subjects: 35
Study 22445005 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (historical control).
Number of subjects: 35
Study 22445005 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy and temozolomide (historical control).
Number of subjects: 35
Study 22446154 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-month daily pelvic floor muscle (PFM) strengthening exercise program at home
Number of subjects: 68
Study 22447794 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR-positive for P. falciparum in peripheral and/or placental blood samples
Number of subjects: 272
Study 22447794 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR-positive placental infections
Number of subjects: 272
Study 22447794 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR-positive but negative in peripheral blood by microscopy or HRP2 RDT in plasma
Number of subjects: 272
Study 22447793 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 480
Study 22447809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (40 or 80 mg)
Number of subjects: 20
Study 22447863 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the retina using a group of 2 × 2 adjacent electrodes at upper comfortable stimulation amplitude
Number of subjects: 9
Study 22447863 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing stimulation pulse rate
Number of subjects: 9
Study 22448814 — intervention group
Group type: EXPERIMENTAL
Intervention: BCX1777 (forodesine) 100 mg/day
Number of subjects: 13
Study 22448814 — intervention group
Group type: EXPERIMENTAL
Intervention: BCX1777 (forodesine) 200 mg/day
Number of subjects: 13
Study 22448814 — intervention group
Group type: EXPERIMENTAL
Intervention: BCX1777 (forodesine) 300 mg/day
Number of subjects: 13
Study 22448921 — intervention group
Group type: EXPERIMENTAL
Intervention: Combotox (low-dose) + Cytarabine (Ara-C)
Number of subjects: 0
Study 22448921 — intervention group
Group type: EXPERIMENTAL
Intervention: Combotox (high-dose) + Cytarabine (Ara-C)
Number of subjects: 0
Study 22448921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of Ara-C and Combotox
Number of subjects: 0
Study 22448921 — intervention group
Group type: COMPARATOR
Intervention: Concurrent administration of Ara-C and Combotox
Number of subjects: 0
Study 22448928 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 784
Study 22449204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0
Study 22449204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and heparin
Number of subjects: 0
Study 22449224 — intervention group
Group type: COMPARATOR
Intervention: Conventional vestibular rehabilitation
Number of subjects: 80
Study 22449224 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality based vestibular rehabilitation (Nintendo Wii Fit Plus®)
Number of subjects: 80
Study 22450529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP blocks with bilateral injections of 20 ml ropivacaine 0.5% w/v (total dose 200 mg)
Number of subjects: 21
Study 22450943 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent chocolate consumption
Number of subjects: 0
Study 22450943 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22451421 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor XIII (rFXIII) prophylaxis
Number of subjects: 41
Study 22451423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bendamustine (75 mg/m² on days 1 and 2), lenalidomide (10 mg on days 1-21), and dexamethasone (40 mg weekly) in a 28-day cycle
Number of subjects: 29
Study 22451423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bendamustine, lenalidomide, and dexamethasone
Number of subjects: 29
Study 22452895 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 50 mg daily
Number of subjects: 129
Study 22452895 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg daily
Number of subjects: 129
Study 22452895 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 129
Study 22452895 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 129
Study 22453048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild stunting
Number of subjects: 351
Study 22453048 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe stunting
Number of subjects: 351
Study 22453048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild underweight
Number of subjects: 351
Study 22453048 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe underweight
Number of subjects: 351
Study 22453570 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (systematic electrophysiological studies and prophylactic permanent pacing)
Number of subjects: 486
Study 22453570 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive strategy
Number of subjects: 486
Study 22453570 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 486
Study 22454801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15-30 mg/d)
Number of subjects: 263
Study 22454801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (900-1500 mg/d)
Number of subjects: 263
Study 22454801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 263
Study 22454801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 263
Study 22454801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 22455454 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 150 mg eq (234 mg) administered via deltoid injection, with subsequent once-monthly injections of the same dose.
Number of subjects: 212
Study 22456429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg intravenous, four doses every 3 weeks, then every 12 weeks for clinically stable patients)
Number of subjects: 72
Study 22456429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg intravenous)
Number of subjects: 72
Study 22456658 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive control
Number of subjects: 330
Study 22456658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective control
Number of subjects: 330
Study 22456659 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT+ (19 patients)
Number of subjects: 32
Study 22456661 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-criteria model (≥ 2 of 3 abnormal ferritin < 12 μg/L, soluble transferrin receptor (TfR) > 8.3 mg/L, zinc protoporphyrin (ZP) > 80 μmol/mol)
Number of subjects: 680
Study 22456661 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ferritin alone
Number of subjects: 680
Study 22456661 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal TfR alone
Number of subjects: 680
Study 22456661 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ZP alone
Number of subjects: 680
Study 22456661 — intervention group
Group type: EXPERIMENTAL
Intervention: TfR/ferritin index (ID > 500)
Number of subjects: 680
Study 22456661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted values for low ferritin and elevated TfR/ferritin index
Number of subjects: 680
Study 22456661 — intervention group
Group type: EXPERIMENTAL
Intervention: TfR
Number of subjects: 680
Study 22456661 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis for TfR
Number of subjects: 680
Study 22456662 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc depletion (10 d, 0.3 mg Zn/d)
Number of subjects: 9
Study 22456662 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc repletion (7 d, 29.5 mg Zn/d)
Number of subjects: 9
Study 22456662 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acclimation (7 d, 10.4 mg Zn/d)
Number of subjects: 9
Study 22456695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 174
Study 22456695 — intervention group
Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 174
Study 22456695 — intervention group
Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 174
Study 22456695 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of OGTT to FPG and HbA1c
Number of subjects: 174
Study 22457087 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fluid balance (FB)
Number of subjects: 100
Study 22457244 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 0
Study 22457291 — intervention group
Group type: EXPERIMENTAL
Intervention: S. epidermidis isolates from cultures
Number of subjects: 75
Study 22457291 — intervention group
Group type: EXPERIMENTAL
Intervention: Disseminated clones
Number of subjects: 75
Study 22457291 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD-related infections
Number of subjects: 75
Study 22457855 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet adherence
Number of subjects: 698
Study 22457855 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction with diagnosis
Number of subjects: 698
Study 22457855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lapses and negative attitude
Number of subjects: 698
Study 22457855 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-patient communication
Number of subjects: 698
Study 22457855 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for young and asymptomatic patients
Number of subjects: 698
Study 22458289 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for sexually transmitted infections (STIs) including chlamydia, trichomonas, and gonorrhea
Number of subjects: 245
Study 22458289 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors and sexual behavior analysis
Number of subjects: 245
Study 22458427 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 22461458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study 22461458 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies based on identified mutations and alterations in protein expression
Number of subjects: 0
Study 22465214 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge test (MCT)
Number of subjects: 219
Study 22465288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based heart failure telemonitoring system
Number of subjects: 100
Study 22465355 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer commercial EHR with robust clinical decision support (CDS) for e-prescribing
Number of subjects: 19
Study 22465355 — intervention group
Group type: COMPARATOR
Intervention: Older locally developed EHR with minimal clinical decision support (CDS) for e-prescribing
Number of subjects: 19
Study 22465364 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival sirolimus (30 μL, 1320 μg)
Number of subjects: 5
Study 22466348 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (300-1200 mg daily)
Number of subjects: 50
Study 22467666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg on day 1) plus Trastuzumab (8 mg/kg on day 1 of cycle 1, 6 mg/kg on day 1 of each subsequent cycle) plus Capecitabine (1,000 mg/m2 twice daily, days 1-14) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
Number of subjects: 88
Study 22467666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Trastuzumab, and Capecitabine combination therapy.
Number of subjects: 88
Study 22469445 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medication use
Number of subjects: 109
Study 22469445 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department visits
Number of subjects: 109
Study 22469445 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled physician visits
Number of subjects: 109
Study 22469445 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive allergen skin test results
Number of subjects: 109
Study 22469445 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 109
Study 22469445 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation problems
Number of subjects: 109
Study 22469621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic autonomic failure patients
Number of subjects: 10
Study 22469621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglionic blocker trimethaphan
Number of subjects: 10
Study 22469621 — intervention group
Group type: COMPARATOR
Intervention: Sedentary healthy controls
Number of subjects: 10
Study 22469860 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010-11 TIV (1 or 2 doses)
Number of subjects: 207
Study 22470077 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Operating Procedures (SOPs)
Number of subjects: 1637
Study 22471287 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA, mycophenolate sodium (MPA) plus corticosteroids (n = 6)
Number of subjects: 20
Study 22471287 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA and everolimus plus corticosteroids (n = 8)
Number of subjects: 20
Study 22471287 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-free (CsA(free)) receiving everolimus, MPA and corticosteroids (n = 6)
Number of subjects: 20
Study 22471287 — intervention group
Group type: COMPARATOR
Intervention: CsA (reg)
Number of subjects: 20
Study 22471287 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in CCR5(+) CXCR3(+) co-expressing CD4(+) FoxP3(-) T cells
Number of subjects: 20
Study 22471378 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component rehabilitation intervention including online monitoring of function with feedback and self-management workshops
Number of subjects: 60
Study 22471378 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 22471422 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatments
Number of subjects: 8
Study 22471947 — intervention group
Group type: EXPERIMENTAL
Intervention: Offline Positron-Emission-Tomography (PET) quality assurance
Number of subjects: 240
Study 22471947 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vivo verification
Number of subjects: 240
Study 22471947 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific patient-population information
Number of subjects: 240
Study 22472035 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (12 × 3 Gy E to 18 × 3 Gy E)
Number of subjects: 0
Study 22472035 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy
Number of subjects: 0
Study 22474060 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase 90 μg/kg
Number of subjects: 179
Study 22474060 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase 125 μg/kg
Number of subjects: 179
Study 22474060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 22474060 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase (pooled data from DIAS, DEDAS, and DIAS-2)
Number of subjects: 179
Study 22475206 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide treatment for 6 months
Number of subjects: 0
Study 22475563 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of all dental amalgam restorations and replacement with other dental restorative materials.
Number of subjects: 20
Study 22475563 — intervention group
Group type: COMPARATOR
Intervention: Reference group (healthy blood donors matched for age and gender).
Number of subjects: 20
Study 22476554 — intervention group
Group type: EXPERIMENTAL
Intervention: rAHF-PFM (Advate®)
Number of subjects: 55
Study 22476856 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg/day
Number of subjects: 139
Study 22480772 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab induction therapy (160 mg/80 mg at Weeks 0/2), followed by 40 mg every other week for up to 20 weeks (40 mg weekly for flares/non-response after Week 12)
Number of subjects: 945
Study 22481227 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 12
Study 22481227 — intervention group
Group type: COMPARATOR
Intervention: 2-PS(opt)
Number of subjects: 12
Study 22483191 — intervention group
Group type: EXPERIMENTAL
Intervention: E-test method applied directly on bronchoalveolar lavage (BAL) samples
Number of subjects: 20
Study 22483191 — intervention group
Group type: COMPARATOR
Intervention: Microbroth dilution approach (control method)
Number of subjects: 20
Study 22483327 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization (IR) defined by residual SYNTAX score (rSS) >0
Number of subjects: 2686
Study 22483327 — intervention group
Group type: COMPARATOR
Intervention: Complete revascularization (CR) defined by residual SYNTAX score (rSS) = 0
Number of subjects: 2686
Study 22483327 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (rSS) >8.0 after PCI
Number of subjects: 2686
Study 22483327 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (rSS) as a predictor
Number of subjects: 2686
Study 22483418 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery pulse wave analysis (PWA)
Number of subjects: 531
Study 22483738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent temozolomide (TMZ)
Number of subjects: 24
Study 22484295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV) 7, PCV10, PCV13
Number of subjects: 8261
Study 22487286 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) in minority patients
Number of subjects: 0
Study 22487286 — intervention group
Group type: COMPARATOR
Intervention: National survey data
Number of subjects: 0
Study 22487286 — intervention group
Group type: COMPARATOR
Intervention: Systematic literature review
Number of subjects: 0
Study 22487286 — intervention group
Group type: COMPARATOR
Intervention: Prospective cohort analysis
Number of subjects: 0
Study 22490331 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation (autoSCT)
Number of subjects: 169
Study 22490397 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickOpt(TM) optimization method
Number of subjects: 101
Study 22490397 — intervention group
Group type: COMPARATOR
Intervention: Standard echocardiographic optimization
Number of subjects: 101
Study 22490397 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of AVTI achieved at optimal settings
Number of subjects: 101
Study 22490570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with taxane therapy (docetaxel or paclitaxel)
Number of subjects: 202
Study 22490570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with taxane therapy
Number of subjects: 202
Study 22491018 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab, a humanized monoclonal antibody targeting the IL-6 receptor
Number of subjects: 1683
Study 22491195 — intervention group
Group type: EXPERIMENTAL
Intervention: CCFSw (Composite Cerebellar Functional Severity Score with the writing test)
Number of subjects: 226
Study 22491195 — intervention group
Group type: EXPERIMENTAL
Intervention: SARA (Scale for the Assessment and Rating of Ataxia)
Number of subjects: 226
Study 22491406 — intervention group
Group type: EXPERIMENTAL
Intervention: POD-Bonferroni
Number of subjects: 167
Study 22491406 — intervention group
Group type: EXPERIMENTAL
Intervention: POD k-FWER
Number of subjects: 167
Study 22491406 — intervention group
Group type: EXPERIMENTAL
Intervention: POD-FDR
Number of subjects: 167
Study 22491406 — intervention group
Group type: EXPERIMENTAL
Intervention: POD k-FWER with retinal height change ≥50 μm
Number of subjects: 167
Study 22491406 — intervention group
Group type: EXPERIMENTAL
Intervention: TCA-liberal
Number of subjects: 167
Study 22491406 — intervention group
Group type: EXPERIMENTAL
Intervention: TCA-moderate
Number of subjects: 167
Study 22491406 — intervention group
Group type: EXPERIMENTAL
Intervention: TCA-conservative
Number of subjects: 167